Clinical Trial

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

Study acronym: eVOLVE-HNSCC
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2028-04-18 -> 2030-04-17 2026-06-25
minor Completion pushed: 2030-09-12 -> 2031-02-28 2026-06-25
Trial Details
NCT Number NCT06129864
Lead Sponsor AstraZeneca
Conditions Locally Advanced Head and Neck Squamous Cell Carcinoma
Enrollment 1,145 participants
Start Date 2023-12-14
Primary Completion 2030-04-17 (estimated)
Study Completion 2031-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-06